- Home
- ACAD vs FHB Comparison
ACAD vs FHB Comparison
Compare ACAD & FHB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACAD
- FHB
- Stock Information
- Founded
- ACAD 1993
- FHB 1858
- Country
- ACAD United States
- FHB United States
- Employees
- ACAD N/A
- FHB N/A
- Industry
- ACAD Biotechnology: Pharmaceutical Preparations
- FHB Major Banks
- Sector
- ACAD Health Care
- FHB Finance
- Exchange
- ACAD Nasdaq
- FHB Nasdaq
- Market Cap
- ACAD 2.8B
- FHB N/A
- IPO Year
- ACAD 2004
- FHB 2016
- Fundamental
- Price
- ACAD $16.61
- FHB $24.53
- Analyst Decision
- ACAD Buy
- FHB Sell
- Analyst Count
- ACAD 17
- FHB 8
- Target Price
- ACAD $24.00
- FHB $28.25
- AVG Volume (30 Days)
- ACAD 1.5M
- FHB 961.4K
- Earning Date
- ACAD 05-07-2025
- FHB 04-25-2025
- Dividend Yield
- ACAD N/A
- FHB 4.28%
- EPS Growth
- ACAD N/A
- FHB N/A
- EPS
- ACAD 1.36
- FHB 1.79
- Revenue
- ACAD $957,797,000.00
- FHB $793,791,000.00
- Revenue This Year
- ACAD $13.07
- FHB $9.90
- Revenue Next Year
- ACAD $9.97
- FHB $4.52
- P/E Ratio
- ACAD $12.28
- FHB $13.57
- Revenue Growth
- ACAD 31.85
- FHB N/A
- 52 Week Low
- ACAD $14.15
- FHB $19.48
- 52 Week High
- ACAD $20.68
- FHB $28.80
- Technical
- Relative Strength Index (RSI)
- ACAD 36.91
- FHB 39.10
- Support Level
- ACAD $16.86
- FHB $23.95
- Resistance Level
- ACAD $17.31
- FHB $25.38
- Average True Range (ATR)
- ACAD 0.51
- FHB 0.60
- MACD
- ACAD -0.00
- FHB 0.04
- Stochastic Oscillator
- ACAD 23.24
- FHB 33.10
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.